Sidney Kennedy

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi The sex effects scale: pilot validation in a healthy population
    Sidney H Kennedy
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Psychopharmacol Bull 43:15-25. 2010
  2. ncbi A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder
    Sidney H Kennedy
    University Health Network, University of Toronto, Ontario, Canada
    Int Clin Psychopharmacol 26:151-8. 2011
  3. ncbi Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis
    Sidney H Kennedy
    Department of Psychiatry, University of Toronto, University Health Network, Ont
    J Psychiatry Neurosci 31:122-31. 2006
  4. ncbi Sexual function during bupropion or paroxetine treatment of major depressive disorder
    Sidney H Kennedy
    University of Toronto, Ontario
    Can J Psychiatry 51:234-42. 2006
  5. ncbi Treatment resistant depression--advances in somatic therapies
    Sidney H Kennedy
    University Health Network and University of Toronto, Toronto, Ontario, Canada
    Ann Clin Psychiatry 19:279-87. 2007
  6. ncbi Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial
    Sidney H Kennedy
    University Health Network, Institute of Medical Science, University of Toronto, Department of Psychiatry, and Toronto General Hospital, 200 Elizabeth St, Eaton North Wing 8 222, Toronto, Ontario M5G 2C4, Canada
    Am J Psychiatry 164:778-88. 2007
  7. ncbi A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR
    Sidney H Kennedy
    Department of Psychiatry, University of Toronto, and University Health Network, 200 Elizabeth Street, Toronto, Ontario, Canada
    J Clin Psychopharmacol 28:329-33. 2008
  8. ncbi Treating each and every depressed patient
    S H Kennedy
    University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Psychopharmacol 22:19-23. 2008
  9. ncbi Core symptoms of major depressive disorder: relevance to diagnosis and treatment
    Sidney H Kennedy
    Department of Psychiatry, University Health Network, University of Toronto, Ontario, Canada
    Dialogues Clin Neurosci 10:271-7. 2008
  10. ncbi Escitalopram in the treatment of major depressive disorder: a meta-analysis
    Sidney H Kennedy
    University of Toronto, Toronto, Ontario, Canada
    Curr Med Res Opin 25:161-75. 2009

Detail Information

Publications91

  1. ncbi The sex effects scale: pilot validation in a healthy population
    Sidney H Kennedy
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Psychopharmacol Bull 43:15-25. 2010
    ..The aim of this study is to validate the Sex Effects scale (SexFX) in a healthy population, addressing internal and inter-rater reliability, test-retest reliability, as well as convergent and divergent validity...
  2. ncbi A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder
    Sidney H Kennedy
    University Health Network, University of Toronto, Ontario, Canada
    Int Clin Psychopharmacol 26:151-8. 2011
    ..01). The most common adverse events included headache, dyspepsia, vasodilatation, and respiratory tract infections and were generally mild in intensity...
  3. ncbi Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis
    Sidney H Kennedy
    Department of Psychiatry, University of Toronto, University Health Network, Ont
    J Psychiatry Neurosci 31:122-31. 2006
    ..We conducted a meta-analysis of studies in which escitalopram was compared with other antidepressants to assess the relative efficacy of these agents...
  4. ncbi Sexual function during bupropion or paroxetine treatment of major depressive disorder
    Sidney H Kennedy
    University of Toronto, Ontario
    Can J Psychiatry 51:234-42. 2006
    ....
  5. ncbi Treatment resistant depression--advances in somatic therapies
    Sidney H Kennedy
    University Health Network and University of Toronto, Toronto, Ontario, Canada
    Ann Clin Psychiatry 19:279-87. 2007
    ....
  6. ncbi Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial
    Sidney H Kennedy
    University Health Network, Institute of Medical Science, University of Toronto, Department of Psychiatry, and Toronto General Hospital, 200 Elizabeth St, Eaton North Wing 8 222, Toronto, Ontario M5G 2C4, Canada
    Am J Psychiatry 164:778-88. 2007
    ..In this study, the authors report changes in fluorine-18-fluorodeoxyglucose PET in responders to CBT or venlafaxine during a randomized controlled trial...
  7. ncbi A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR
    Sidney H Kennedy
    Department of Psychiatry, University of Toronto, and University Health Network, 200 Elizabeth Street, Toronto, Ontario, Canada
    J Clin Psychopharmacol 28:329-33. 2008
    ..2%, vs venlafaxine XR, 8.6%). Agomelatine seems to be an efficacious antidepressant with a superior sexual side effect profile compared with venlafaxine XR, although superiority to placebo was not evaluated in this trial...
  8. ncbi Treating each and every depressed patient
    S H Kennedy
    University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Psychopharmacol 22:19-23. 2008
    ....
  9. ncbi Core symptoms of major depressive disorder: relevance to diagnosis and treatment
    Sidney H Kennedy
    Department of Psychiatry, University Health Network, University of Toronto, Ontario, Canada
    Dialogues Clin Neurosci 10:271-7. 2008
    ..Careful clinical evaluation should address all of these dimensions, recognizing that improvement may occur sooner in some symptoms (eg, mood) compared with others (eg, sleep disturbance)...
  10. ncbi Escitalopram in the treatment of major depressive disorder: a meta-analysis
    Sidney H Kennedy
    University of Toronto, Toronto, Ontario, Canada
    Curr Med Res Opin 25:161-75. 2009
    ..To assess the relative antidepressant efficacy of escitalopram and comparator antidepressants...
  11. ncbi Sexual dysfunction, depression, and the impact of antidepressants
    Sidney H Kennedy
    Department of Psychiatry, University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 29:157-64. 2009
    ..The purpose of this review was to provide an update on the prevalence, psychobiology, and relative adverse effect burden of sexual dysfunction associated with different antidepressants...
  12. ncbi Emerging drugs for major depressive disorder
    Sidney H Kennedy
    University of Toronto, Department of Psychiatry, 200 Elizabeth Street, 8EN 222, Toronto, ON M5G 2C4, Canada
    Expert Opin Emerg Drugs 14:439-53. 2009
    ..This review will discuss the scientific rationale for these targets, as well as highlight the current status of drugs in development...
  13. ncbi Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies
    Sidney H Kennedy
    University of Toronto, Canada
    J Affect Disord 117:S44-53. 2009
    ..There is renewed interest in refined approaches to brain stimulation, particularly for treatment resistant major depressive disorder (MDD)...
  14. ncbi Agomelatine: efficacy at each phase of antidepressant treatment
    Sidney H Kennedy
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 23:41-7. 2009
    ..The recent registration of agomelatine by the European Medicines Agency now offers the potential of fulfilling many currently unmet clinical needs throughout the time course of management of MDD...
  15. ncbi Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder
    Sidney Kennedy
    University Health Network Psychiatry, Toronto, ON, Canada
    J Sex Med 7:3449-59. 2010
    ..Flibanserin, a novel 5-HT(1A) agonist and 5-HT(2A) antagonist, has the potential to treat sexual dysfunction...
  16. ncbi Frequency and correlates of gambling problems in outpatients with major depressive disorder and bipolar disorder
    Sidney H Kennedy
    University of Toronto, Ontario, Canada
    Can J Psychiatry 55:568-76. 2010
    ....
  17. ncbi Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years
    Sidney H Kennedy
    Department of Psychiatry, Division of Neurosurgery, University Health Network, Toronto, Canada
    Am J Psychiatry 168:502-10. 2011
    ..This report represents an extended follow-up of 20 patients with treatment-resistant depression who received DBS to the subcallosal cingulate gyrus (Brodmann's area 25)...
  18. ncbi Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
    S H Kennedy
    University Health Network, Toronto, ON, Canada
    Eur Neuropsychopharmacol 16:93-100. 2006
    ..These results support the prescription of agomelatine 25 mg as the usual therapeutic dose, and suggest that increasing the dose to 50 mg may be beneficial for some patients without reducing tolerability...
  19. ncbi Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial
    Sidney H Kennedy
    University of Toronto, The University Health Network, Toronto, Ontario, Canada
    J Clin Psychiatry 64:439-44. 2003
    ..Despite increasing evidence that full symptomatic remission is the optimal goal of antidepressant therapy, there have been few comparisons between disparate treatment approaches to achieve this goal...
  20. ncbi Strategies to achieve clinical effectiveness: refining existing therapies and pursuing emerging targets
    Sidney H Kennedy
    University Health Network, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Affect Disord 132:S21-8. 2011
    ..This is of particular importance when considering the long term use of antidepressant therapies for relapse prevention...
  21. ncbi Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics
    Sidney H Kennedy
    University Health Network, 200 Elizabeth Street, Eaton North, 8th Floor, Room 222 Toronto, ON M5G 2C4, Canada
    Bipolar Disord 5:36-47. 2003
    ..With today's therapeutic alternatives, full remission of depression is an attainable goal. For some patients, combination and augmentation strategies earlier in treatment may increase the likelihood of remission...
  22. ncbi Pharmacotherapy to sustain the fully remitted state
    Sidney Kennedy
    Mood and Anxiety Disorders Program, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 27:269-80. 2002
    ..Medication should continue at the dose that was initially effective because using low-dose maintenance therapy appears to decrease the protective benefits...
  23. ncbi Full remission: a return to normal functioning
    Sidney Kennedy
    Mood and Anxiety Disorders Program, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 27:233-4. 2002
  24. ncbi Reboxetine: a preliminary report on its use through the Special Access Program
    Sidney H Kennedy
    University Health Network, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 27:418-22. 2002
    ..To describe the effectiveness and tolerability of reboxetine under Special Access Program conditions in Canada in a group of patients with refractory depressive disorders...
  25. ncbi Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
    Bipolar Disord 7:5-69. 2005
    ..These guidelines also discuss issues related to bipolar disorder in women and those with comorbidity and include a section on safety and monitoring...
  26. ncbi Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada
    Bipolar Disord 8:721-39. 2006
    ..The importance of comorbid psychiatric and medical conditions cannot be understated, and this update provides an expanded look at the prevalence, impact and management of comorbid conditions in patients with bipolar disorder...
  27. ncbi Cognitive reactivity to sad mood provocation and the prediction of depressive relapse
    Zindel V Segal
    Department of Psychiatry, University of Toronto, Toronto, Ontario
    Arch Gen Psychiatry 63:749-55. 2006
    ..Episode remission in unipolar major depression, while distinguished by minimal symptom burden, can also be a period of marked sensitivity to emotional stress as well as an increased risk of relapse...
  28. ncbi Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy
    Kimberly Goldapple
    Rotman Research Institute at Baycrest Centre, 3560 Bathurst Street, Toronto, Ontario, Canada M6A 2E1
    Arch Gen Psychiatry 61:34-41. 2004
    ..Unique directional changes in frontal cortex, cingulate, and hippocampus with CBT relative to paroxetine may reflect modality-specific effects with implications for understanding mechanisms underlying different treatment strategies...
  29. ncbi Changes in autobiographical memory specificity following cognitive behavior therapy and pharmacotherapy for major depression
    Carolina McBride
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Psychopathology 40:147-52. 2007
    ..Overgeneral memory is considered as a stable cognitive trait that is intrinsically linked with depression and independent of mood state. Previous studies show that autobiographical memory is modifiable...
  30. ncbi The relationship between testosterone and sexual function in depressed and healthy men
    Sakina J Rizvi
    University Health Network, Department of Psychiatry, Toronto, Canada
    J Sex Med 7:816-25. 2010
    ..The objective of this study is to evaluate the effects of depression and low testosterone across various domains of sexual function...
  31. ncbi Combining antidepressants for treatment-resistant depression: a review
    Raymond W Lam
    Division of Mood Disorders, Department of Psychiatry, University of British Columbia, UBC Hospital, Vancouver, British Columbia, Canada
    J Clin Psychiatry 63:685-93. 2002
    ..This review critically evaluates the evidence for efficacy of combining antidepressants...
  32. ncbi Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Mood and Anxiety Disorders Program, Center for Addiction and Mental Health, Clarke Site, Ontario, Canada
    Bipolar Disord 4:207-13. 2002
    ....
  33. ncbi Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder
    Jakub Z Konarski
    University Health Network, Toronto General Hospital, 200 Elizabeth St, Eaton North Wing 8 222, Toronto ON M5G2C4
    J Psychiatry Neurosci 34:175-80. 2009
    ..Longitudinal neuroimaging investigations of antidepressant treatment offer the opportunity to identify potential baseline biomarkers associated with poor outcome...
  34. ncbi The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8
    Headache 46:973-82. 2006
    ..Opportunistic screening and surveillance for bipolar and comorbid migraine is warranted...
  35. ncbi Assessing full remission
    Roger McIntyre
    Mood and Anxiety Disorders Program, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 27:235-9. 2002
    ..A score of 3 or less on the Toronto HAM-D7 was found to correlate with the 17-item HAM-D definition of full remission (i.e., score of 7 or less)...
  36. ncbi Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial
    Arun V Ravindran
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychiatry 69:87-94. 2008
    ..To evaluate the efficacy, safety, and tolerability of adjunctive osmotic-release oral system (OROS) methylphenidate in outpatients with major depressive disorder (MDD) receiving a stable oral antidepressant regimen...
  37. ncbi Neural stimulation successfully treats depression in patients with prior ablative cingulotomy
    Joseph S Neimat
    Toronto Western Hospital, 399 Bathurst St, WW4-425, Toronto, Ontario M5T 2S8, Canada
    Am J Psychiatry 165:687-93. 2008
  38. ncbi Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada
    Bipolar Disord 11:225-55. 2009
    ..Bipolar II disorder is frequently overlooked in treatment guidelines, but has an important clinical impact on patients' lives. This update provides an expanded look at bipolar II disorder...
  39. ncbi Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects
    Sidney H Kennedy
    Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 63:181-6. 2002
    ..CONCLUSION: Bupropion had an effect on the pharmacokinetics of venlafaxine but not those of the SSRIs. Further investigation of combination treatments under randomized, double-blind conditions is recommended...
  40. ncbi Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 68:1352-7. 2007
    ..This investigation was undertaken to explore the relationship between alcohol/illicit drug dependence and overweight/obesity in individuals with bipolar I disorder...
  41. ncbi Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    Ann Clin Psychiatry 19:257-64. 2007
    ..A nascent explanatory theory regarding the pathophysiology of major depressive disorder posits that alterations in metabolic networks (e.g., insulin and glucocorticoid signaling) mediate allostasis...
  42. ncbi Comparing features of bipolar disorder to major depressive disorder in a tertiary mood disorders clinic
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    Ann Clin Psychiatry 19:313-7. 2007
    ..We sought to describe features that distinguish individuals with bipolar disorder from major depressive disorder...
  43. ncbi The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, ON, Canada
    Adv Ther 27:828-36. 2010
    ..To our knowledge, this is the first study reporting on the rate of metabolic syndrome in a Canadian clinical sample and exclusively evaluating asymptomatic individuals...
  44. ncbi The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 24:741-53. 2010
    ..Initiating and maintaining antidepressant therapy should include routine surveillance for clinical and/or biochemical evidence suggestive of the metabolic syndrome...
  45. ncbi The hepatic safety profile of duloxetine: a review
    Roger S McIntyre
    University Health Network, Mood Disorders Psychopharmacology Unit, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
    Expert Opin Drug Metab Toxicol 4:281-5. 2008
    ..Hepatotoxicity related to the use of duloxetine resulted in rewording of the US product insert...
  46. ncbi Clinical guidelines for depressive disorders. Summary of recommendations relevant to family physicians
    Sidney H Kennedy
    University Health Network, University of Toronto, Ontario
    Can Fam Physician 49:489-91. 2003
  47. ncbi Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, ON, Canada
    Expert Opin Pharmacother 10:3061-75. 2009
    ..The data from the studies reviewed herein also indicate that quetiapine XR poses a low risk for extrapyramidal side effects in middle-aged and elderly individuals with major depressive disorder...
  48. ncbi The relationship between childhood abuse and suicidality in adult bipolar disorder
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, University Health Network, Toronto, Ontario, Canada
    Violence Vict 23:361-72. 2008
    ..Anamnestic inquiry regarding childhood maltreatment is salient to risk assessment, illness management planning, preventative strategies, and treatment interventions in bipolar disorder...
  49. ncbi Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication
    Sagar V Parikh
    University of Toronto, Canada
    J Affect Disord 117:S15-25. 2009
    ..This article, one of five in the series, reviews new studies of psychotherapy in the acute and maintenance phase of MDD, including computer-based and telephone-delivered psychotherapy...
  50. ncbi Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Toronto, ON, Canada
    Expert Opin Pharmacother 8:1615-28. 2007
    ..Extant data provide the basis for formulating a hypothesis that TZDs may be salutary for cognitive deficits and several aspects of somatic health (e.g., cardiovascular disease) associated with mood disorders...
  51. ncbi Medical comorbidity in bipolar disorder: re-prioritizing unmet needs
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Psychiatry 20:406-16. 2007
    ..The aim of this review is to synthesize results from extant investigations which report on the co-occurrence of bipolar disorder and medical comorbidity...
  52. ncbi Improving outcomes in depression: a focus on somatic symptoms
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Psychosom Res 60:279-82. 2006
    ..It is hypothesized that somatic symptom alleviation is a significant predictor of overall outcome in depressed primary care patients...
  53. ncbi Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Ontario
    Can J Psychiatry 51:274-80. 2006
    ..We further aimed to examine the likelihood of an association between obesity and MD, while controlling for the influence of sociodemographic variables...
  54. ncbi Calculated bioavailable testosterone levels and depression in middle-aged men
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Psychoneuroendocrinology 31:1029-35. 2006
    ..We sought to determine the relationship between physiologically active bioavailable testosterone (BT) and depressive symptoms in middle-aged men with and without major depressive disorder (MDD)...
  55. ncbi A dimensional approach to personality in atypical depression
    Kevin K Chopra
    Department of Psychiatry, University of Toronto, c o CAMH Room 1121, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Psychiatry Res 134:161-7. 2005
    ..In sum, the FFM provides a new understanding of which unique personality characteristics may be associated with atypical depression...
  56. ncbi Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario, Canada
    Psychiatr Serv 57:1140-4. 2006
    ..This is the first cross-national population-based investigation exploring the prevalence and functional implications of comorbid general medical disorders in bipolar disorder...
  57. ncbi Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street Toronto, ON, M5T 2S8, Canada
    Expert Opin Pharmacother 7:1305-21. 2006
    ..Antidiabetic treatments, which maintain euglycaemia, hold promise as potent and clinically significant therapeutic interventions for several neuropsychiatric disorders...
  58. ncbi Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    Ann Clin Psychiatry 17:83-93. 2005
    ..Preliminary investigations indicate that patients who suffer from BD with comorbid DM have a more severe course and outcome, lower quality of life, higher prevalence of medical comorbidity and higher cost of illness...
  59. ncbi Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale
    Roger S McIntyre
    University of Toronto, Toronto, Ont
    CMAJ 173:1327-34. 2005
    ..We evaluated a 7-item abbreviated version (HAMD-7) of the 17-item Hamilton Depression Rating Scale (HAMD-17) in a randomized controlled clinical trial of patients with major depressive disorder being cared for in primary care settings...
  60. ncbi The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, University Health Network, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
    Expert Opin Drug Saf 5:157-68. 2006
    ..To synthesise results from investigations reporting on the effect of antidepressants on glucose-insulin homeostasis...
  61. ncbi Deep brain stimulation for treatment-resistant depression: a psychiatric perspective
    Peter Giacobbe
    University Health Network, 200 Elizabeth Street, EN8-222, Toronto, Ontario M5G 2C4, Canada
    Curr Psychiatry Rep 8:437-44. 2006
    ....
  62. ncbi Anxiety disorders and bipolar disorder: a review
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University Health Network, University of Toronto, 399 Bathurst Street, Toronto, Ontario, Canada
    Bipolar Disord 8:665-76. 2006
    ..Taken together, a compelling basis emerges for prioritizing the identification and management of anxiety symptomatology in the BPD population...
  63. ncbi Antipsychotic-induced weight gain: bipolar disorder and leptin
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 23:323-7. 2003
    ..05). The temporal association between weight increase and leptin changes does not support the notion that leptin is a primary promoter of antipsychotic-induced weight gain; however, a secondary perpetuating role cannot be ruled out...
  64. ncbi Residual anxiety symptoms in depressed primary care patients
    Roger S McIntyre
    University of Toronto, Toronto, Ontario, Canada
    J Psychiatr Pract 13:125-8. 2007
    ..The goal of this study was to characterize the burden of anxiety among residual depressive symptoms in naturalistic primary care settings...
  65. ncbi A comparison of antidepressant response in younger and older women
    Sophie Grigoriadis
    University Health Network, EN8 229, University of Toronto, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, Canada M5G 2C4
    J Clin Psychopharmacol 23:405-7. 2003
    ..This may relate to changes in menstrual status. Limitations of the study and implications for the role of female sex hormones are discussed. Future investigations should include measurement of reproductive hormone levels...
  66. ncbi Problem gambling in bipolar disorder: results from the Canadian Community Health Survey
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Affect Disord 102:27-34. 2007
    ..This investigation was undertaken to explore the prevalence and associated features of problem gambling amongst individuals with bipolar I disorder...
  67. ncbi The effect of antidepressants on lipid homeostasis: a cardiac safety concern?
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Toronto, ON, Canada
    Expert Opin Drug Saf 5:523-37. 2006
    ..The authors sought to summarise and synthesise results from investigations which report on the effect of antidepressants on serum lipid homeostasis...
  68. ncbi EEG correlates of acute and chronic paroxetine treatment in depression
    Verner Knott
    Department of Psychiatry and Psychology, University of Ottawa Royal Ottawa Hospital and Institute of Mental Health Research, Ottawa, ON, Canada
    J Affect Disord 69:241-9. 2002
    ..The chronic pharmaco-EEG response pattern reflects both sedating and activating actions in regional specific areas which are relevant to the pathophysiology and the pharmacotherapeutic treatment of depression...
  69. ncbi The antidepressant effects of risperidone and olanzapine in bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario
    Can J Clin Pharmacol 11:e218-26. 2004
    ..To describe the antidepressant effectiveness of olanzapine and risperidone and compare their tolerability when employed adjunctively in bipolar I/II disorder...
  70. ncbi Deep brain stimulation for treatment-resistant depression
    Helen S Mayberg
    Rotman Research Institute at Baycrest Centre, and Departments of Psychiatry and Neurology, University of Toronto, Toronto, Ontario, M6A 2E1, Canada
    Neuron 45:651-60. 2005
    ....
  71. ncbi Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness
    Sidney H Kennedy
    Department of Psychiatry, University Health Network, Toronto, Ontario, Canada
    CNS Drugs 24:479-99. 2010
    ....
  72. ncbi Relationship between regional brain metabolism, illness severity and age in depressed subjects
    Jakub Z Konarski
    Institute of Medical Science, University of Toronto, Toronto, ON, Canada
    Psychiatry Res 155:203-10. 2007
    ..The age-dependent changes documented herein may influence the distinct clinical presentation and treatment response described in older-age depression...
  73. ncbi A novel examination of atypical major depressive disorder based on attachment theory
    Robert D Levitan
    Department of Psychiatry, University of Toronto, Mood and Anxiety Division, Centre for Addiction and Mental Health, c o CAMH, Toronto, Ontario, Canada
    J Clin Psychiatry 70:879-87. 2009
    ..As gender has been an important consideration in prior work on atypical depression, this same hypothesis was further tested in female subjects only...
  74. ncbi Sex differences in hormonal responses to a social stressor in chronic major depression
    Kevin K Chopra
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Psychoneuroendocrinology 34:1235-41. 2009
    ..The current study evaluated cortisol stress responses to a social challenge in chronic major depressive disorder (CMDD)...
  75. ncbi Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy
    R Michael Bagby
    Centre for Addiction and Mental Health, Toronto, Ontario
    Can J Psychiatry 53:361-70. 2008
    ..The objective of this investigation was to determine if patient personality characteristics are predictive of response to either cognitive-behavioural therapy (CBT) or pharmacotherapy (PHT)...
  76. ncbi Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders?
    Joanna K Soczynska
    University of Toronto, Institute of Medical Science, Toronto, ON, Canada
    Expert Opin Investig Drugs 17:827-43. 2008
    ..Mood disorders are associated with decrements in cognitive function, which are insufficiently treated with contemporary pharmacotherapies...
  77. ncbi Omega-3 supplements in pregnancy: are we too late to identify the possible benefits?
    Sophie Grigoriadis
    Department of Psychiatry, University Health Network, Toronto ON, Canada
    J Obstet Gynaecol Can 32:209-16. 2010
    ....
  78. ncbi Treatment guidelines for mania
    Sidney H Kennedy
    Bipolar Guidelines Group, Canadian Network for Mood and Anxiety Treatments, Department of Psychiatry, University of Toronto, University Health Network, Toronto, Ont
    J Psychiatry Neurosci 31:144. 2006
  79. ncbi Dimensional personality traits and treatment outcome in patients with major depressive disorder
    Lena C Quilty
    Clinical Research Department, Centre for Addiction and Mental Health, Canada
    J Affect Disord 108:241-50. 2008
    ..This study investigated the association between dimensional personality traits from the Five-Factor Model (FFM) and treatment outcome in patients with Major Depressive Disorder (MDD)...
  80. ncbi Sex differences in antidepressant response in a Canadian primary-care sample
    Sophie Grigoriadis
    J Clin Psychopharmacol 27:95-8. 2007
  81. ncbi Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses
    Raymond W Lam
    Department of Psychiatry, University of British Columbia, Vancouver
    Can J Psychiatry 49:17S-26S. 2004
    ..Randomized controlled clinical trials conducted in the last 5 years provide very good evidence to show that achieving and sustaining the fully remitted state is an attainable goal in the management of patients with depression...
  82. ncbi Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine
    J D Vanderkooy
    Queen's University, Kingston, Ontario
    Can J Psychiatry 47:174-80. 2002
    ..CONCLUSIONS: These results confirm the clinical utility of the TSES as a simple, clinician-administered antidepressant side-effect scale...
  83. ncbi Neuroimaging approaches in mood disorders: technique and clinical implications
    Jakub Z Konarski
    Mood Disorders Psychopharmacology Unit, University Health Network, ON, Canada
    Ann Clin Psychiatry 19:265-77. 2007
    ..The encompassing aim of this review is to provide the mental health care practitioner with a pragmatic understanding of neuroimaging approaches and their possible clinical application...
  84. ncbi The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective
    Robert D Levitan
    Mood and Anxiety Division, Centre for Addiction and Mental Health, University of Toronto, Department of Psychiatry, 250 College Street, Room 1126, Toronto, Ontario M5T 1R8, Canada
    Biol Psychiatry 56:665-9. 2004
    ..In this study, we examined whether binge eating behavior mediated this putative association...
  85. ncbi Antidepressant augmentation with raloxifene
    Sophie Grigoriadis
    J Clin Psychopharmacol 25:96-8. 2005
  86. ncbi Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function
    Lakshmi N Ravindran
    J Clin Psychopharmacol 28:107-8. 2008
  87. ncbi Low-dose dexamethasone challenge in women with atypical major depression: pilot study
    Robert D Levitan
    Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 27:47-51. 2002
    ..To examine if atypical depression may be associated with hypersuppression of the hypothalamic-pituitary-adrenal (HPA) axis...
  88. ncbi Using metaanalysis to evaluate evidence: practical tips and traps
    Raymond W Lam
    Division of Clinical Neuroscience, Department of Psychiatry, University of British Columbia, Vancouver
    Can J Psychiatry 50:167-74. 2005
    ..This paper focuses on basic principles and terms used in metaanalysis, so that clinicians can appropriately evaluate and use their results to guide treatment decisions...
  89. ncbi Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm
    Jeffrey H Meyer
    Vivian M Rakoff PET Imaging Centre, Clarke Division, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College St, Toronto, ON, M5T 1R8, Canada
    Am J Psychiatry 160:90-9. 2003
    ....
  90. ncbi The 5-factor model of personality and antidepressant medication compliance
    Nicole L Cohen
    Department of Psychiatry, University Health Network, Toronto, Ontario
    Can J Psychiatry 49:106-13. 2004
    ..Identifying predictors of medication compliance may help in the development of individualized treatment regimens and lead to improved therapeutic outcome in the treatment of MDD...
  91. ncbi Advances in treatment of mood and anxiety disorders: focus on atypical antipsychotics
    Lakshmi N Yatham
    University of British Columbia, Vancouver, BC
    Bipolar Disord 5:5-6. 2003